J. Clin. Oncol. 2019 Oct 16
Improving Adjuvant Endocrine Treatment Tailoring in Premenopausal Women With Hormone Receptor–Positive Breast Cancer
ABSTRACT
The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors’ suggested management approaches. The goal of this series is to help readers better understand how to apply the results of key studies, including those published in Journal of Clinical Oncology, to patients seen in their own clinical practice.
Related Questions
New comment by Medical Oncologist at Conway Regional Health System ( March 14, 2020)
So if the patient is pre menopausal at the end of 5 yrs, OFS can be stopped and just continue Tamoxifen for node negative and consider AI for high risk disease?
For example, is this still your approach in women with small tumors or node negative disease?
New answer by Medical Oncologist at IRCCS Policlinico San Martino Hospital – University of Genova (January 9, 2020)
According to our guidelines, age per se should not be considered a reason for administering more aggressive treatments (including chemotherapy and/or a more aggressive endocri...
Data from the SOFT/TEXT trials showed clinical benefit in ovarian suppression + aromatase inhibition for high risk, premenopausal ...
New answer by Medical Oncologist at Mayo Clinic Rochester (May 29, 2020)
I agree with @Kathy Miller—if the patient has no desire for future pregnancy, I usually advocate for BSO. If future pregnancy is a possibility, I switch to tamoxifen or ...